Exclusive Distribution Agreement for Cerebrovascular Products in the U.S. Market
First written in FY2019-Q3. 2 of 5 entries say "Advanced", first in FY2019. Latest entry: FY2021.
No other company in this theme has enough history to compare yet.
- FY2021RestatedAnnual report
「In addition to PTCA guidewires, we will continue to strengthen our other proprietary-brand product lines and OEM business in an effort to expand earnings.」
The policy of extending direct sales in the United States to proprietary-brand products other than PTCA guidewires and to the OEM business is being continued. - FY2021-Q3AdvancedAnnual report
「② Similarly, in the United States, direct sales of cerebrovascular products began in January 2021.」
The transition in U.S. cerebrovascular products from sales based on the existing exclusive distribution agreement to direct sales in January 2021 is described as having been implemented. - FY2021-Q2Transition from exclusive agency sales to direct salesAnnual report
「Similarly, in the United States, we decided to begin direct sales of cerebrovascular products in January 2021.」
The company decided to transition from sales based on its existing exclusive distribution agreement with a major U.S. medical-device manufacturer to direct sales from January 2021. - FY2019AdvancedAnnual report
「In addition, transactions have tended to increase, particularly in the second half, including inventory supply, and sales have increased, following the execution in November 2018 of an exclusive distribution agreement in the U.S. market with a major medical-device manufacturer for cerebrovascular products in the non-cardiovascular field.」
Following the execution of an exclusive distribution agreement for cerebrovascular products with a major U.S. medical-device manufacturer, transactions and sales increased, particularly in the second half. - FY2019-Q3First statedAnnual report
「Execution of an exclusive distribution agreement for cerebrovascular products in the U.S. market」
The execution of an exclusive distribution agreement to sell cerebrovascular products in the U.S. market is separately identified for the first time as an initiative implemented during the first nine months of the fiscal year under review.